152 related articles for article (PubMed ID: 8439971)
1. In vitro and in vivo targeting of gene expression to melanoma cells.
Vile RG; Hart IR
Cancer Res; 1993 Mar; 53(5):962-7. PubMed ID: 8439971
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.
Lillehammer T; Tveito S; Engesaeter BO; Fodstad O; Maelandsmo GM; Engebraaten O
Cancer Gene Ther; 2005 Nov; 12(11):864-72. PubMed ID: 15891771
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells.
Siders WM; Halloran PJ; Fenton RG
Cancer Res; 1996 Dec; 56(24):5638-46. PubMed ID: 8971169
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus.
Siders WM; Halloran PJ; Fenton RG
Cancer Gene Ther; 1998; 5(5):281-91. PubMed ID: 9824047
[TBL] [Abstract][Full Text] [Related]
5. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA.
Vile RG; Hart IR
Cancer Res; 1993 Sep; 53(17):3860-4. PubMed ID: 8395331
[TBL] [Abstract][Full Text] [Related]
6. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma.
Schoensiegel F; Paschen A; Sieger S; Eskerski H; Mier W; Rothfels H; Kleinschmidt J; Schadendorf D; Haberkorn U
Cancer Gene Ther; 2004 Jun; 11(6):408-18. PubMed ID: 15118759
[TBL] [Abstract][Full Text] [Related]
7. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.
Ram Z; Culver KW; Walbridge S; Blaese RM; Oldfield EH
Cancer Res; 1993 Jan; 53(1):83-8. PubMed ID: 8380127
[TBL] [Abstract][Full Text] [Related]
8. A novel nonviral cytoplasmic gene expression system and its implications in cancer gene therapy.
Chen X; Li Y; Xiong K; Xie Y; Aizicovici S; Snodgrass R; Wagner TE; Platika D
Cancer Gene Ther; 1995 Dec; 2(4):281-9. PubMed ID: 8548582
[TBL] [Abstract][Full Text] [Related]
9. Cotransfection of genes encoding human tyrosinase and tyrosinase-related protein-1 prevents melanocyte death and enhances melanin pigmentation and gene expression of Lamp-1.
Luo D; Chen H; Jimbow K
Exp Cell Res; 1994 Jul; 213(1):231-41. PubMed ID: 8020595
[TBL] [Abstract][Full Text] [Related]
10. Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development.
Wiznerowicz M; Fong AZ; Mackiewicz A; Hawley RG
Gene Ther; 1997 Oct; 4(10):1061-8. PubMed ID: 9415312
[TBL] [Abstract][Full Text] [Related]
11. An oncolytic adenoviral vector carrying the tyrosinase promoter for glioma gene therapy.
Ulasov IV; Rivera AA; Nettelbeck DM; Rivera LB; Mathis JM; Sonabend AM; Tyler M; Wang M; Douglas JT; Lesniak MS
Int J Oncol; 2007 Nov; 31(5):1177-85. PubMed ID: 17912445
[TBL] [Abstract][Full Text] [Related]
12. A safe, effective in vivo gene therapy for melanoma using tyrosinase promoter-driven cytosine deaminase gene.
Cao G; Zhang X; He X; Chen Q; Qi Z
In Vivo; 1999; 13(2):181-7. PubMed ID: 10363176
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes.
Vile R; Miller N; Chernajovsky Y; Hart I
Gene Ther; 1994 Sep; 1(5):307-16. PubMed ID: 7584096
[TBL] [Abstract][Full Text] [Related]
14. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component.
Emiliusen L; Gough M; Bateman A; Ahmed A; Voellmy R; Chester J; Diaz RM; Harrington K; Vile R
Gene Ther; 2001 Jul; 8(13):987-98. PubMed ID: 11438833
[TBL] [Abstract][Full Text] [Related]
15. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
16. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
17. Tissue specific promoters in targeting systemically delivered gene therapy.
Hart IR
Semin Oncol; 1996 Feb; 23(1):154-8. PubMed ID: 8607025
[TBL] [Abstract][Full Text] [Related]
18. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
19. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.
Vile RG; Nelson JA; Castleden S; Chong H; Hart IR
Cancer Res; 1994 Dec; 54(23):6228-34. PubMed ID: 7954471
[TBL] [Abstract][Full Text] [Related]
20. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors.
Duguay D; Mercier F; Stagg J; Martineau D; Bramson J; Servant M; Lin R; Galipeau J; Hiscott J
Cancer Res; 2002 Sep; 62(18):5148-52. PubMed ID: 12234977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
